Cidara Therapeutics Announces Multiple Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Cidara Therapeutics, Inc. (CDTX)
Last cidara therapeutics, inc. earnings: 3/4 05:55 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cidara.com
Company Research
Source: Business Wire
Six poster presentations include new analyses from Phase 2 STRIVE clinical trial of rezafungin Four oral presentations include first scientific presentation of new data highlighting the potential of its Cloudbreak antiviral conjugates (AVCs) for influenza SAN DIEGO--(BUSINESS WIRE)-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced a total of 10 upcoming presentations summarizing data on the company’s lead antifungal rezafungin and its Cloudbreak antiviral program at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). The company and its collaborators will deliver four oral and six poster presentations at the meeting being held in Amsterdam, Netherlands from April 13 to 16, 2019. “The data to be presented at ECCMID will add to the growing body of evidence dem
Show less
Read more
Impact Snapshot
Event Time:
CDTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CDTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CDTX alerts
High impacting Cidara Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CDTX
News
- Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024 [Yahoo! Finance]Yahoo! Finance
- Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024GlobeNewswire
- CIDARA Therapeutics ALERT: Bragar Eagel & Squire, P.C. is Investigating Cidara Therapeutics, Inc. on Behalf of Cidara Therapeutics Stockholders and Encourages Investors to Contact the FirmGlobeNewswire
- Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its "strong-buy" rating re-affirmed by analysts at WBB Securities. They now have a $40.00 price target on the stock.MarketBeat
- Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its price target raised by analysts at Needham & Company LLC from $3.00 to $25.00. They now have a "buy" rating on the stock.MarketBeat
CDTX
Earnings
- 11/2/23 - Beat
CDTX
Sec Filings
- 4/24/24 - Form 8-K
- 4/24/24 - Form 8-K
- 4/23/24 - Form S-8
- CDTX's page on the SEC website